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REVIEW
Abstract: Anti-TNFα therapy has revolutionized the treatment of rheumatoid arthritis (RA) 
and other inﬂ  ammatory diseases. These drugs are powerful and expensive. A new anti-TNFα 
agent, a nanomolecule comprising a humanized Fab' antibody fragment against TNFα with a 
polyethylene glycol tail, is shortly to complete phase III trials in RA. In this review we will 
discuss the construct of this new molecule, data from trials so far, and its potential place in the 
market place.
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Targeting tumour necrosis factor alpha (TNFα) 
in rheumatoid arthritis
Rheumatoid arthritis (RA) is a chronic inﬂ  ammatory disease. It is characterized by 
synovial inﬂ  ammation, but in addition there are major systemic and extra-articular 
features. The prevalence of RA is estimated at 1% and it is associated with a high 
degree of morbidity and signiﬁ  cant mortality (Felts and Yelin 1989).
The exact cause of RA has not yet been established, but it appears that in a 
genetically predisposed person immune system dysregulation drives the development 
and maintenance of this chronic disease. Over recent years an important role has been 
identiﬁ  ed for the proinﬂ  ammatory cytokine TNFα in the pathogenesis of RA. Cultured 
RA synovial cells produce many proinﬂ  ammatory cytokines. Antibodies against 
TNFα introduced to these cultures do not only inhibit the activity of TNFα, they also 
reduce the production of other inﬂ  ammatory cytokines (IL1, IL6, IL8) (Brennan et al 
1989). In this respect, TNFα appears to orchestrate and perpetuate the inﬂ  ammatory 
response in RA by increasing proinﬂ  ammatory cytokines and recruitment of immune 
cells, stimulating cell proliferation, and mediating the destruction of bone and cartilage 
(Brennan et al 1989). The concentration of TNFα is elevated in the joints and the blood 
of patients with RA (Chu et al 1991). Animal models also support a central role for 
TNFα in inﬂ  ammatory arthritis (Keffer et al 1991).
Three drugs targeting TNFα are now in common clinical use: inﬂ  iximab (a chimeric 
TNFα speciﬁ  c monoclonal antibody with mouse hypervariable domains and human 
antibody backbone); adalimumab (a recombinant human TNFα speciﬁ  c monoclonal 
antibody); and etanercept (a fully human construct comprising the p75 TNFα receptor 
and Fc antibody portion). The efﬁ  cacy of these agents in controlling the symptoms 
and signs of RA is further evidence that in many patients with RA TNFα is a central 
pathogenic mediator.
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Certolizumab pegol
There are two important regions of antibodies, the Fab 
and the Fc portions (Figure 1). The Fab portion contains 
complimentarity-determining regions (CDR), unique 
sequences of amino acids responsible for binding antigen. The 
Fc portion is not antigen speciﬁ  c but acts as a backbone and is 
necessary for other antibody functions including complement 
ﬁ  xation and cell lysis. Monoclonal antibodies have a single 
identical sequence, in contrast to polyclonal antibodies, which 
have many different sequences and hence antigen-binding 
properties. The ﬁ  rst generation of monoclonal antibodies 
were generated in mice, but the immunogenicity of murine 
proteins in humans precluded their use therapeutically, 
due to their propensity to induce major immune responses 
(anaphylaxis). Thereafter, strategies have been developed 
to limit the immunogenicity of monoclonal antibodies. 
One such strategy is that of “humanization”. This involves 
replacement of murine framework sequences around the 
CDR with human framework sequences. Certolizumab pegol 
has been developed using this technique. It consists of only 
the Fab' portion (50 kD) of a monoclonal antibody directed 
against TNFα, with humanized framework sequences and a 
2x20  kD pegol domain (Figure 2). The resulting molecule 
contains only the smallest effective antigen-binding part 
of the monoclonal antibody and is thus referred to as a 
nanomolecule. The murine part is reduced to a minimum with 
a parallel reduction in potential for immunogenicity. 
Mechanism of action and 
pharmacokinetics
Certolizumab pegol binds to TNFα and prevents its 
interaction with specific receptors, hence neutralizing 
it. Studies have demonstrated that it is more potent at 
neutralizing membrane-bound TNF than etanercept and 
more potent at neutralizing soluble TNF than adalimumab 
and inﬂ  iximab (Gramlick et al 2006). It lacks an Fc portion 
and is therefore unable to ﬁ  x complement or to lyse cells 
with surface-bound TNFα, in contrast to inﬂ  iximab and 
adalimumab (Fossati and Nesbitt 2006a). As it is derived 
from a monoclonal antibody, certolizumab pegol does not 
bind lymphotoxin (TNFβ), in contrast to etanercept (Mpofu 
et al 2005). Certolizumab has also been shown to be the only 
anti-TNF agent that does not kill activated lymphocytes and 
monocytes by apoptosis or increase levels of degranulation 
and necrosis of granulocytes in vitro (Fossati and Nesbitt 
2006b). The potential consequences of these structural 
properties are discussed below.
As a nanomolecule, the Fab' would have a much shorter 
half-life than other monoclonal antibodies and therefore the 
disadvantage of requiring a more frequent administration. 
Therefore the Fab' is bound to a polyethylene glycol moiety 
(PEG), which increases its half-life and potentially further 
decreases its immunogenicity. The plasma half-life in 
humans is 13 days, which is comparable to that of full length 
humanized antibodies (Baker et al 2006). This allows a 
once-monthly, subcutaneous dosing regime. This has been 
conﬁ  rmed in a phase II study in 36 RA patients (Choy et al 
2002).
Figure 1  Antibody structure.
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Figure 2  Certolizumab pegol. 
Abbreviations: CD, complimentarity domain; C, constant region; 
CH, constant heavy chain region; PEG, pegol domain; V, variable region.
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Efﬁ  cacy and safety studies
Phase I studies
The results of phase I studies were released in 1999. They 
demonstrated that therapeutic doses of certolizumab pegol 
were well tolerated and produced no serious side-effects 
in healthy volunteers. Both intravenous and subcutaneous 
administration yielded similar results (Kaushik and Moots 
2005).
Phase II studies in RA
The ﬁ  rst phase II study was published in 2002. This was 
a double-blind, randomized, placebo-controlled trial of 
certolizumab pegol given intravenously as a single infusion 
at 1, 5, or 20 mg/kg in 36 patients. Patients were included if 
they had severe active disease as deﬁ  ned as >3 swollen and 
6 tender joints and an ESR >29. The response was measured 
according to the American College of Rheumatology 
(ACR) response criteria where an ACR20 indicates a 20% 
clinical improvement from baseline after treatment and an 
ACR50 and ACR70 indicate a 50% or 70% improvement, 
respectively. An ACR20 was designed to show difference 
between drug and placebo, but ACR50 and ACR70 responses 
are clinically meaningful to patients. The study showed a dose 
response, with the 1 mg/kg dose being no better than placebo, 
but signiﬁ  cant responses at higher doses. The 20 mg/kg dose 
showed no clear beneﬁ  t over the 5 mg/kg dose in the ACR20 
response (75% vs 75%, respectively, at 8 weeks), but did show 
an increase in the number of patients achieving an ACR50 
(50% and 12.5%, respectively, at 8 weeks). The treatment 
was well tolerated, with no infusion-related reactions. There 
was 1 lower respiratory tract infection in the placebo group 
and 3 in the treatment groups. These were described as mild 
to moderate. One severe adverse event was reported. This 
was an episode of neck pain experienced 3 days after infusion 
with the lowest dose of 1 mg/kg of certolizumab pegol. An 
increase in the titre of antinuclear antibodies was seen in 4 
patients, 1 in the placebo group and 3 in the treatment groups; 
however, no change was found in the double stranded DNA 
titre or anticardiolipin antibodies. There was 1 death in the 
treatment group, from a pericardial effusion that was not due 
to infection and was felt by the investigator to be unrelated 
to the drug (Choy et al 2002).
A second trial was a multicenter, randomized, double-
blind, placebo-controlled, dose ranging, phase II study 
of subcutaneous certolizumab pegol. Patients were given 
50, 100, 200, or 400  mg of certolizumab pegol or placebo 
subcutaneously every 4 weeks for 12 weeks. The response 
was measured using the ACR criteria outlined above. Again, 
there was a clear dose response. Patients receiving 400 mg 
achieved an ACR20 of 60%, ACR50 of 40%, and ACR70 
of 29% at 12 weeks. In addition, patients receiving 400 mg 
also had an improvement in their health-related quality of 
life. Again the drug was well tolerated (Keystone et al 2001; 
Pharmacia Corp 2001; Emery et al 2002)
The results of a third trial involving 660 patients were 
disclosed by Celltech in 2002, showing that patients receiving 
400 mg of certolizumab pegol subcutaneously achieved an 
ACR20 of 75% at 7 days post a single injection (Kaushik 
and Moots 2005).
Phase III studies in RA
Several phase III trials of certolizumab pegol in RA are 
underway and complete phase III data are awaited. Trials are 
exploring the use of certolizumab pegol as a monotherapy and 
also in combination with methotrexate. Patients recruited had 
severe active disease with at least 9 tender and swollen joints 
and either an ESR >30 mm/h or CRP >15 mg/L. Evidence 
from previous trials using anti-TNF therapies demonstrates 
that the addition of methotrexate can give additive beneﬁ  t 
in patients with RA (Hyrich et al 2006). A press release 
(UCB Pharma 2004) in September 2004 from Celltech did 
report positive preliminary results from phase III studies 
of certolizumab pegol in RA as monotherapy in terms of 
the primary endpoint (ACR20). Patients receiving the drug 
had signiﬁ  cant ACR20 responses at 1 week, maintained for 
the duration of the study. In addition they reported similar 
positive results from the trials assessing combination with 
methotrexate. Adverse events were similar to those seen in 
phase I and II studies (UCB Pharma 2004). The delay in 
publication of phase III studies appears to be for business 
rather than clinical reasons and the ﬁ  nal results are expected 
in late 2006 or early 2007.
Patient implications
Pegylation reduces immunogenicity by shielding the protein 
from recognition by the immune system (Mehvar 2000). 
Because of the pegylated formulation of the nanomolecule 
certolizumab pegol, immunogenicity of the drug is minimized 
and half-life increased. This has the dual beneﬁ  t that the drug 
can be administered less frequently (monthly) and that it 
is less likely to induce anti-drug antibody formation than 
conventional chimeric monoclonal antibodies. Reduced 
immunogenicity, due to humanization and pegylation, not 
only means that severe allergic reactions are less likely, but 
also that the development of neutralizing antibodies may be International Journal of Nanomedicine 2007:2(1) 6
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reduced. The latter can be responsible for the phenomenon of 
“dose creep” where the dose of a drug needs to be increased, 
or the interval between doses decreased, to maintain clinical 
response. The intravenous dose ranging phase II study 
revealed that following a single dose of certolizumab pegol 
no or only low levels of antibodies were identiﬁ  ed. Following 
a second infusion, however, antibodies were detected in all 
treatment groups (1  mg/kg, 5  mg/kg, 20  mg/kg). Although 
the incidence of antibodies varied, the trend was for less 
antibodies with increased dose (Choy et al 2002). The clinical 
effect of these antibodies will be revealed only by phase III 
studies, and whether they are neutralizing (and therefore 
translate into dose creep or late inefﬁ  cacy) will become fully 
apparent only with later open label extensions.
The Fab fragment of a monoclonal antibody does not 
require glycosylation for function and therefore this drug 
can be produced in Escherichia coli, a bacterial host. This 
makes the production of certolizumab pegol potentially less 
expensive than existing anti-TNFα therapies. If this were to 
translate into cheaper drug costs and assuming comparable 
efﬁ  cacy and safety to other anti-TNFα agents, there may 
be pressure from purchasers to favor a less expensive drug, 
and/or allow treatment of more patients with RA, at earlier 
stages of disease.
Certolizumab pegol does not have an Fc portion and 
therefore is not capable of complement ﬁ  xation or lysis of 
cells expressing cell surface TNFα. Etanercept is reported 
to be not capable of complement ﬁ  xation – a property that 
has been suggested to underlie its slightly safer proﬁ  le in 
relation to the rate of intracellular infections compared 
with inﬂ  iximab and adalimumab (Moots et al 2003). A 
recent study, however, has contradicted this report, showing 
that etanercept but not certolizumab pegol is capable of 
complement mediated cell lysis (Fossati and Nesbitt 2006a). 
It may therefore follow that certolizumab pegol will share 
this lower rate of intracellular infections (Moots et al 2003). 
However, as well as neutralizing TNFα, etanercept will also 
bind to and neutralize a related pro-inﬂ  ammatory cytokine, 
lymphotoxin (TNFβ), whereas certolizumab pegol does 
not. The role of lymphotoxin in RA is not fully known, but 
in at least one individual, it would appear that neutralizing 
this cytokine in RA has beneﬁ  cial effects (Buch et al 2004). 
Certolizumab pegol is reported not to lyse activated immune 
cells in vitro. This may have implications for its efﬁ  cacy in 
treating inﬂ  ammatory conditions but equally may make it 
more speciﬁ  c and therefore reduce the side-effect proﬁ  le in 
terms of infection risk. Certainly the reports, quoted above, 
suggest that unlike other anti-TNFα agents, it does not lead 
to granulocyte degranulation and necrosis are likely to be 
positive overall in terms of safety and efﬁ  cacy.
Conclusions: place in market
Certolizumab pegol is a keenly awaited addition to the family 
of anti-TNFα agents for the treatment of inﬂ  ammatory 
diseases. Although this is already a busy market place, 
certolizumab pegol has some features that might make it 
an attractive option: the long half-life allows a fortnightly, 
subcutaneous drug regime and might even allow monthly 
drug administration in the future; the lack of complement 
ﬁ  xation may impart less risk of intracellular infection than 
the monoclonal antibody anti-TNFα agents and the potential 
to be produced more cheaply than other anti-TNFα agents 
may have a major inﬂ  uence on purchasers. 
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